Plain-English translation of NCT06706791 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called empagliflozin to see if it can help improve quality of life in people living with both chronic heart failure and type 2 diabetes. Empagliflozin is a diabetes medication, but recent research suggests it may also benefit the heart. This study will compare people taking the medication alongside their regular heart failure treatment to people taking a placebo (a pill with no active ingredient) to see which group reports better quality of life.
Heart failure and type 2 diabetes often occur together, and both can seriously affect how people feel day-to-day. While this medication is already used for diabetes, researchers want to understand whether it can make a real difference in how heart failure patients feel and function in their everyday lives.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll be randomly assigned to either take the medication or a placebo once daily by mouth, both alongside your regular heart failure treatments. The study lasts 18 months, and researchers will ask you to fill out questionnaires about how you're feeling and how heart failure is affecting your daily life. You'll participate at one of two hospitals in Karachi, Pakistan.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Pakistan